Guideline

British Association of Dermatologists guidelines for biologic therapy for psoriasis

Read time: 1 mins

Last updated:1st Oct 2020

Source: British Association of Dermatologists

Status: live

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use of biologic therapies targeting tumour necrosis factor (TNF) (adalimumab, etanercept, certolizumab pegol, infliximab), interleukin (IL)‐12/23p40 (ustekinumab), IL‐17A (ixekizumab, secukinumab), IL‐17RA (brodalumab) and IL‐23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. This rapid update is part of an annual evidence review to factor in the latest evidence for biological drugs evaluated in the 2017 publication of the guideline,1 and newer biological drugs that have been licensed for psoriasis in the UK or are expected to be licensed in the near future.

Read full guideline